181 related articles for article (PubMed ID: 35889565)
1. Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease.
Rodríguez-Castejón J; Gómez-Aguado I; Beraza-Millor M; Solinís MÁ; Del Pozo-Rodríguez A; Rodríguez-Gascón A
Nanomaterials (Basel); 2022 Jul; 12(14):. PubMed ID: 35889565
[TBL] [Abstract][Full Text] [Related]
2. α-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice.
Rodríguez-Castejón J; Alarcia-Lacalle A; Gómez-Aguado I; Vicente-Pascual M; Solinís Aspiazu MÁ; Del Pozo-Rodríguez A; Rodríguez-Gascón A
Pharmaceutics; 2021 May; 13(6):. PubMed ID: 34064206
[TBL] [Abstract][Full Text] [Related]
3. Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy.
Ruiz de Garibay AP; Delgado D; Del Pozo-Rodríguez A; Solinís MÁ; Gascón AR
Drug Des Devel Ther; 2012; 6():303-10. PubMed ID: 23118528
[TBL] [Abstract][Full Text] [Related]
4. Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review.
Rodríguez-Castejón J; Beraza-Millor M; Solinís MÁ; Rodríguez-Gascón A; Del Pozo-Rodríguez A
Drug Deliv Transl Res; 2024 Apr; ():. PubMed ID: 38587758
[TBL] [Abstract][Full Text] [Related]
5. Solid Lipid Nanoparticles as Non-Viral Vectors for Gene Transfection in a Cell Model of Fabry Disease.
Ruiz de Garibay AP; Solinís MA; del Pozo-Rodríguez A; Apaolaza PS; Shen JS; Rodríguez-Gascón A
J Biomed Nanotechnol; 2015 Mar; 11(3):500-11. PubMed ID: 26307832
[TBL] [Abstract][Full Text] [Related]
6. Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterization and in vivo transfection after intravenous administration to mice.
Delgado D; Gascón AR; Del Pozo-Rodríguez A; Echevarría E; Ruiz de Garibay AP; Rodríguez JM; Solinís MÁ
Int J Pharm; 2012 Apr; 425(1-2):35-43. PubMed ID: 22226874
[TBL] [Abstract][Full Text] [Related]
7. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
8. Naked plasmid DNA-based alpha-galactosidase A gene transfer partially reduces systemic accumulation of globotriaosylceramide in Fabry mice.
Nakamura G; Maruyama H; Ishii S; Shimotori M; Kameda S; Kono T; Miyazaki J; Kulkarni AB; Gejyo F
Mol Biotechnol; 2008 Feb; 38(2):109-19. PubMed ID: 18219591
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
Choi JO; Lee MH; Park HY; Jung SC
J Biomed Sci; 2010 Apr; 17(1):26. PubMed ID: 20398385
[TBL] [Abstract][Full Text] [Related]
10. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
11. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period.
Ogawa K; Hirai Y; Ishizaki M; Takahashi H; Hanawa H; Fukunaga Y; Shimada T
Mol Genet Metab; 2009 Mar; 96(3):91-6. PubMed ID: 19091614
[TBL] [Abstract][Full Text] [Related]
12. Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease.
Ziegler RJ; Li C; Cherry M; Zhu Y; Hempel D; van Rooijen N; Ioannou YA; Desnick RJ; Goldberg MA; Yew NS; Cheng SH
Hum Gene Ther; 2002 May; 13(8):935-45. PubMed ID: 12031126
[TBL] [Abstract][Full Text] [Related]
13. Design flexibility influencing the in vitro behavior of cationic SLN as a nonviral gene vector.
Vighi E; Montanari M; Hanuskova M; Iannuccelli V; Coppi G; Leo E
Int J Pharm; 2013 Jan; 440(2):161-9. PubMed ID: 22982257
[TBL] [Abstract][Full Text] [Related]
14. Sequencing and characterization of the porcine α-galactosidase A gene: towards the generation of a porcine model for Fabry disease.
Yoshimitsu M; Higuchi K; Fan X; Takao S; Medin JA; Tei C; Takenaka T
Mol Biol Rep; 2011 Jun; 38(5):3145-52. PubMed ID: 20131008
[TBL] [Abstract][Full Text] [Related]
15. Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.
Zhu X; Yin L; Theisen M; Zhuo J; Siddiqui S; Levy B; Presnyak V; Frassetto A; Milton J; Salerno T; Benenato KE; Milano J; Lynn A; Sabnis S; Burke K; Besin G; Lukacs CM; Guey LT; Finn PF; Martini PGV
Am J Hum Genet; 2019 Apr; 104(4):625-637. PubMed ID: 30879639
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-transduced lung as a portal for delivering alpha-galactosidase A into systemic circulation for Fabry disease.
Li C; Ziegler RJ; Cherry M; Lukason M; Desnick RJ; Yew NS; Cheng SH
Mol Ther; 2002 Jun; 5(6):745-54. PubMed ID: 12027559
[TBL] [Abstract][Full Text] [Related]
17. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
[TBL] [Abstract][Full Text] [Related]
18. pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles.
Vighi E; Ruozi B; Montanari M; Battini R; Leo E
Int J Pharm; 2010 Apr; 389(1-2):254-61. PubMed ID: 20100555
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy for Fabry disease.
Siatskas C; Medin JA
J Inherit Metab Dis; 2001; 24 Suppl 2():25-41; discussion 11-2. PubMed ID: 11758676
[TBL] [Abstract][Full Text] [Related]
20. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.
Takahashi H; Hirai Y; Migita M; Seino Y; Fukuda Y; Sakuraba H; Kase R; Kobayashi T; Hashimoto Y; Shimada T
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13777-82. PubMed ID: 12370426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
